Cargando…

Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib

BACKGROUND: Primary and secondary nonresponse to anti-tumor necrosis factor (TNF) therapy is common in patients with ulcerative colitis (UC), yet limited research has compared the effectiveness of subsequent biological therapy. OBJECTIVE: We sought to compare the effectiveness of vedolizumab and tof...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kappelman, Michael D, Long, Millie D, Zhang, Xian, Lin, Feng-Chang, Weisbein, Laura, Chen, Wenli, Burris, Jessica, Dorand, Jennifer E, Parlett, Lauren E, Fehlmann, Tara, Brensinger, Colleen M, Haynes, Kevin, Nair, Vinit, Kaul, Alan F, Dobes, Angela, Lewis, James D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284045/ https://www.ncbi.nlm.nih.gov/pubmed/37350775 http://dx.doi.org/10.1093/crocol/otad031

Ejemplares similares

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection
por: Long, Millie D, et al.
Publicado: (2022)

A Patient-Prioritized Agenda for Information Needs During the COVID-19 Pandemic: A Qualitative Study of Patients With Inflammatory Bowel Disease
por: Long, Millie D, et al.
Publicado: (2021)

Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease
por: Llano, Ernesto M, et al.
Publicado: (2021)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

Mesalazine/tofacitinib/vedolizumab: COVID-19 infection: 3 case reports
Publicado: (2021)

Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease
por: Wiles, C Alex, et al.
Publicado: (2021)

Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study
por: Hajjat, Temara M, et al.
Publicado: (2021)

Sa1061: CROSS-SECTIONAL AND LONGITUDINAL ASCERTAINMENT OF PATIENTS WITH IBD'S PERCEPTIONS AND EXPERIENCES DURING COVID-19: CLAPPED COVID-19
por: Lee, Hanbich, et al.
Publicado: (2022)

Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling
por: Uda, Akihito, et al.
Publicado: (2020)

CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn’s Disease
por: Kwapisz, Lukasz, et al.
Publicado: (2022)

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab
por: Harrington, Jill E, et al.
Publicado: (2020)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study
por: Dotti, Adriana Zanoni, et al.
Publicado: (2023)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab
por: Chiorean, Michael, et al.
Publicado: (2020)

Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
por: Patel, Dipen, et al.
Publicado: (2022)

Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
por: Gagnon, Ann-Lorie, et al.
Publicado: (2021)

Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
por: Perin, Ramir Luan, et al.
Publicado: (2022)

Home Infusions for Inflammatory Bowel Disease Are Safe: US Experience and Patient Perspectives
por: Kochar, Bharati, et al.
Publicado: (2021)

Trends in Surgical Recurrence Among Pediatric Crohn’s Disease Patients Using Administrative Claims Data
por: Egberg, Matthew D, et al.
Publicado: (2023)

Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn’s Disease
por: Dulai, Parambir S, et al.
Publicado: (2022)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2021)

Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data
por: Goss Sawhney, Tia, et al.
Publicado: (2023)

Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS
por: Perlin, David S., et al.
Publicado: (2020)

Cryptococcus neoformans Coinfection Dampens the TNF-α Response in HIV-1-Infected Human THP-1 Macrophages
por: Kalem, Murat C., et al.
Publicado: (2021)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Characteristics of Fecal Microbiota Transplantation Use in Inflammatory Bowel Disease Cohort
por: Bauer, Christina M, et al.
Publicado: (2020)

Trends and Characteristics of Clinical Trials Participation for Inflammatory Bowel Disease in the United States: A Report From IBD Partners
por: Johnson, Cole, et al.
Publicado: (2020)

Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis
por: Hamel, Blaise, et al.
Publicado: (2018)

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2020)

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)

Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
por: Schneider, Anna-Maria, et al.
Publicado: (2018)

Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed
por: Nagano, Katsumasa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kmpdoklpiba91jt4rtqe485690